Carotid artery intervention — the carotid artery stenting (CAS) and transcervical carotid artery revascularization (TCAR) providing minimally invasive alternatives to carotid endarterectomy for stroke prevention — creates a specialized high-stakes peripheral intervention market, with the Peripheral Intervention Market reflecting carotid intervention as a commercially important specialty segment.

Carotid artery stenting commercial market — the Cordis PRECISE, Medtronic Protégé, Abbot Acculink, and Silk Road Medical ENROUTE TCAR platforms representing the commercial carotid intervention device market. The approximately twenty thousand US CAS procedures annually (versus approximately one hundred thousand CEA) demonstrating the limited but growing CAS market from the ongoing debate about CAS versus CEA outcomes.

TCAR (TransCarotid Artery Revascularization) — the Silk Road Medical ENROUTE system enabling stent placement via direct carotid access with flow reversal neuroprotection — represents the commercial innovation achieving significant market penetration from superior neurological protection versus femoral access CAS with cerebral embolic protection filters. TCAR's growing adoption (approximately thirty percent of carotid stenting procedures) creating the premium carotid intervention market.

CREST-2 trial implications — the ongoing randomized trial comparing CAS/TCAR to optimal medical therapy for asymptomatic carotid stenosis — representing the major clinical study that will define future carotid intervention practice. The CREST-2 result potentially contracting the asymptomatic carotid stenosis intervention market if medical therapy demonstrates equivalence.

Do you think TCAR will eventually displace traditional femoral-access CAS as the standard carotid stenting approach from its superior neuroprotection profile?

FAQ

What is TCAR and how does it differ from conventional CAS? TCAR (TransCarotid Artery Revascularization): direct carotid artery access via small neck incision; Silk Road Medical ENROUTE system; flow reversal: blood flows from carotid artery through sheath to filter unit and back to femoral vein — reverses flow during stent deployment; advantage: any embolic debris swept away from brain; superior neuroprotection vs distal filter in femoral CAS; lower stroke risk in registries vs conventional CAS; disadvantages: requires small surgical incision; more invasive than femoral CAS; training required for surgical exposure; growing adoption: approximately thirty percent US carotid stenting; FDA approved; reimbursement similar to CAS.

When is carotid intervention preferred over carotid endarterectomy? CAS/TCAR preferred vs CEA when: high surgical risk (previous neck surgery, radiation, contralateral CEA); cardiac conditions precluding general anesthesia; hostile neck anatomy; restenosis after prior CEA; contralateral laryngeal nerve palsy; anatomically high carotid bifurcation; CEA preferred: standard surgical risk patients (CREST trial: similar outcomes, slight CAS advantage in MI, CEA advantage in stroke); TCAR positioned as equivalent to CEA in high-surgical-risk patients (ROADSTER 2 registry data); asymptomatic stenosis: growing evidence supporting medical therapy alone in some patients.

#PeripheralIntervention #CarotidStenting #TCAR #SilkRoadMedical #CarotidArtery #CASvsEEA